

# Rodney J Hicks

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2757753/rodney-j-hicks-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

475  
papers

20,881  
citations

72  
h-index

127  
g-index

509  
ext. papers

24,942  
ext. citations

5.8  
avg, IF

6.9  
L-index

#	Paper	IF	Citations
475	PET/CT variants and pitfalls in malignant melanoma.. <i>Cancer Imaging</i> , <b>2022</b> , 22, 3	5.6	1
474	Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2022</b> , 49, 1386	8.8	6
473	Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[F]FDG-PET/CT external beam radiation treatment planning in lung cancer.. <i>Radiotherapy and Oncology</i> , <b>2022</b> ,	5.3	1
472	Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF melanoma.. <i>Nature Communications</i> , <b>2022</b> , 13, 1100	17.4	0
471	Imaging immunity in patients with cancer using positron emission tomography.. <i>Npj Precision Oncology</i> , <b>2022</b> , 6, 24	9.8	0
470	The value of the Standardized Uptake Value (SUV) and Metabolic Tumor Volume (MTV) in lung cancer. <i>Seminars in Nuclear Medicine</i> , <b>2022</b> ,	5.4	0
469	Longitudinal changes of focal cortical glucose hypometabolism in adults with chronic drug resistant temporal lobe epilepsy. <i>Brain Imaging and Behavior</i> , <b>2021</b> , 1	4.1	0
468	Combining radionuclide therapy with radiotherapy <b>2021</b> ,		
467	PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211053898	5.4	3
466	FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma. <i>Cancer Imaging</i> , <b>2021</b> , 21, 57	5.6	1
465	Utility of Ga-DOTA-Exendin-4 positron emission tomography-computed tomography imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia. <i>Internal Medicine Journal</i> , <b>2021</b> , 51, 1657-1664	1.6	2
464	Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy. <i>Clinical and Translational Immunology</i> , <b>2021</b> , 10, e1351	6.8	0
463	γ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival. <i>Cancer Immunology Research</i> , <b>2021</b> , 9, 612-623	12.5	3
462	Imaging Somatostatin Positive Tumors with Tyr-Octreotate/Octreotide Conjugated to Desferrioxamine B Squaramide Radiolabeled with either Zirconium-89 or Gallium-68. <i>Bioconjugate Chemistry</i> , <b>2021</b> , 32, 1192-1203	6.3	1
461	High-Specific-Activity-I-MIBG versus Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2989-2995	12.9	8
460	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. <i>European Journal of Cancer</i> , <b>2021</b> , 146, 56-73	7.5	32
459	Intra-patient comparison of physiologic Ga-PSMA-11 and F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay. <i>Cancer Imaging</i> , <b>2021</b> , 21, 35	5.6	1

458	Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 656611	5.3	2
457	A New Turn in Peptide-Based Imaging Agents: Foldamers Afford Improved Theranostics Targeting Cholecystokinin-2 Receptor-Positive Cancer. <i>Journal of Medicinal Chemistry</i> , <b>2021</b> , 64, 4841-4856	8.3	2
456	Cancer Diagnoses Following Abnormal Noninvasive Prenatal Testing: A Case Series, Literature Review, and Proposed Management Model.. <i>JCO Precision Oncology</i> , <b>2021</b> , 5, 1001-1012	3.6	2
455	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. <i>Nature Reviews Endocrinology</i> , <b>2021</b> , 17, 435-444	15.2	12
454	Efficacy and safety of Lu-DOTATATE in lung neuroendocrine tumors: a bi-center study. <i>Journal of Nuclear Medicine</i> , <b>2021</b> ,	8.9	5
453	Radionuclide imaging of NENs. <i>Current Opinion in Endocrine and Metabolic Research</i> , <b>2021</b> , 18, 207-215	1.7	
452	Molecular imaging with FLT: a case of Cassandra's curse?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2687-2689	8.8	
451	Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on Ga-DOTATATE PET/CT and F-FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 204-216	8.8	12
450	Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with Cu. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 829-832	8.9	4
449	FAPI PET/CT: Will It End the Hegemony of F-FDG in Oncology?. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 296-302	8.9	29
448	Nodal metabolic tumour volume on baseline F-FDG PET/CT and overall survival in stage II and III NSCLC patients undergoing curative-intent chemoradiotherapy/radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2021</b> , 65, 748-754	1.7	1
447	Novel RET Fusion Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma.. <i>JCO Precision Oncology</i> , <b>2021</b> , 5, 1160-1165	3.6	1
446	The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. <i>Nature Communications</i> , <b>2021</b> , 12, 5049	17.4	6
445	Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, e200-e205	3.3	5
444	ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , <b>2021</b> , e13040	3.8	4
443	ENETS consensus guidelines for synoptic reporting of radiology studies. <i>Journal of Neuroendocrinology</i> , <b>2021</b> , e13044	3.8	6
442	Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor. <i>Chemical Science</i> , <b>2021</b> , 12, 9004-9016	9.4	1
441	PET Diagnosis and Response Monitoring in Oncology <b>2021</b> , 1049-1076		

440	Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report. <i>Journal of Critical Care</i> , <b>2020</b> , 60, 319-322	4	1
439	Peptide Receptor Radionuclide Therapy with Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1800-1805	8.9	15
438	Technical Note: Rapid multiexponential curve fitting algorithm for voxel-based targeted radionuclide dosimetry. <i>Medical Physics</i> , <b>2020</b> , 47, 4332-4339	4.4	2
437	F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. <i>Cancer Imaging</i> , <b>2020</b> , 20, 36	5.6	24
436	Enhancing the anti-tumour activity of Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP. <i>Scientific Reports</i> , <b>2020</b> , 10, 10196	4.9	18
435	Abscopal Regressions of Lymphoma After Involved-Site Radiation Therapy Confirmed by Positron Emission Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 108, 204-211	4	3
434	Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. <i>Lancet, The</i> , <b>2020</b> , 395, 1208-1216	40	472
433	Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1326-1330	8.9	10
432	Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 2322-2327	8.8	51
431	Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1094-1095	8.9	6
430	The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose ( F) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2020</b> , 16, 150-157	1.9	2
429	FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 2776-2786	8.8	20
428	Carboplatin dosing in the era of IDMS-creatinine; the Cockcroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care. <i>Gynecologic Oncology</i> , <b>2020</b> , 157, 793-798	4.9	3
427	First in-human study of in vivo imaging of ex vivo labeled CAR T cells with dual PET-MR.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3557-3557	2.2	2
426	On the Inclusion of Specialists as Authors in Systematic Reviews. <i>SpringerBriefs in Ethics</i> , <b>2020</b> , 57-66	0.1	
425	Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 64, 250-264 <sup>14</sup>		2
424	Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 1: The Role of F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 943-950	8.9	20
423	Pitfalls and Immune-Related Adverse Events <b>2020</b> , 101-115		1

4 <sup>22</sup>	FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 10041-10041	2.2	
4 <sup>21</sup>	PERCISTence: Strength or Stubbornness?. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 199S-200S	8.9	
4 <sup>20</sup>	Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 857-865	8.9	99
4 <sup>19</sup>	Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 1316-1323	7.5	11
4 <sup>18</sup>	F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond. <i>PET Clinics</i> , <b>2020</b> , 15, 11-22	2.2	12
4 <sup>17</sup>	Radiation Dosimetry in Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1030-1036	8.9	21
4 <sup>16</sup>	Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma <b>2020</b> , 8,		5
4 <sup>15</sup>	The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT. <i>Cancer Imaging</i> , <b>2020</b> , 20, 68	5.6	4
4 <sup>14</sup>	Bivalent Inhibitors of Prostate-Specific Membrane Antigen Conjugated to Desferrioxamine B Squaramide Labeled with Zirconium-89 or Gallium-68 for Diagnostic Imaging of Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , <b>2020</b> , 63, 9258-9270	8.3	7
4 <sup>13</sup>	First clinical study of a pegylated diabody I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers. <i>Theranostics</i> , <b>2020</b> , 10, 11404-11415	12.1	7
4 <sup>12</sup>	Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1553-1559	8.9	7
4 <sup>11</sup>	Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 844-854	4.3	8
4 <sup>10</sup>	Early Outcomes of Surgery for Carcinoid Heart Disease. <i>Heart Lung and Circulation</i> , <b>2020</b> , 29, 742-747	1.8	4
4 <sup>09</sup>	Gallium-68 Ventilation/Perfusion PET-CT and CT Pulmonary Angiography for Pulmonary Embolism Diagnosis: An Interobserver Agreement Study. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 599901	4.9	
4 <sup>08</sup>	The Prognosis and Natural History of In-Transit Melanoma Metastases at a High-Volume Centre. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 4673-4680	3.1	2
4 <sup>07</sup>	A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention. <i>Angewandte Chemie</i> , <b>2019</b> , 131, 15133-15136	3.6	0
4 <sup>06</sup>	How we read: the combined use of MRI and novel PET tracers for the characterisation and treatment planning of masses in neuro-oncology. <i>Cancer Imaging</i> , <b>2019</b> , 19, 57	5.6	4
4 <sup>05</sup>	Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT. <i>EJNMMI Research</i> , <b>2019</b> , 9, 15	3.6	4

404	Peptide Receptor Radiotherapy: Current Approaches and Future Directions. <i>Current Treatment Options in Oncology</i> , <b>2019</b> , 20, 77	5.4	18
403	Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for Lu-labelled PSMA Radioligand Therapy. <i>European Urology Oncology</i> , <b>2019</b> , 2, 670-676	6.7	74
402	The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 5091-5099	5.6	12
401	Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team. <i>BJU International</i> , <b>2019</b> , 124, 551	5.6	11
400	The role of F-FDG-PET/CT in evaluating retroperitoneal masses -Keeping your eye on the ball!. <i>Cancer Imaging</i> , <b>2019</b> , 19, 28	5.6	4
399	PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 1869-1877	8.8	11
398	Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 1902-1910	8.8	26
397	Intra-individual comparison of Ga-PSMA-11 and F-DCFPyL normal-organ biodistribution. <i>Cancer Imaging</i> , <b>2019</b> , 19, 23	5.6	24
396	Independent and incremental value of ventilation/perfusion PET/CT and CT pulmonary angiography for pulmonary embolism diagnosis: results of the PECAN pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 1596-1604	8.8	10
395	The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of F-Fluoromethylcholine or Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 1253-1258	8.9	12
394	Molecular Imaging of Recurrent and Metastatic Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , <b>2019</b> , 49, 280-293	5.4	5
393	CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience. <i>Journal of Oncology</i> , <b>2019</b> , 2019, 9032753	4.5	21
392	Modification of Biodistribution and Brain Uptake of Copper Bis(thiosemicarbazonato) Complexes by the Incorporation of Amine and Polyamine Functional Groups. <i>Inorganic Chemistry</i> , <b>2019</b> , 58, 4540-4552	5.1	12
391	FDG-PET/CT in managing infection in patients with hematological malignancy: clinician knowledge and experience in Australia. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2471-2476	1.9	3
390	Outcome of patients with early-stage follicular lymphoma staged with F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 80-86	8.8	10
389	What F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 328-334	8.9	13
388	A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention. <i>Angewandte Chemie - International Edition</i> , <b>2019</b> , 58, 14991-14994	16.4	16
387	EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 2536-2544	8.8	136

386	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 2112-2137	8.8	113
385	Characterizing high-grade serous papillary carcinoma of tunica vaginalis. <i>Urology Case Reports</i> , <b>2019</b> , 26, 100949	0.5	1
384	Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. <i>Thyroid</i> , <b>2019</b> , 29, 1634-1645	6.2	25
383	Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. <i>Blood</i> , <b>2019</b> , 134, 756-756	2.2	15
382	Automated preparation of clinical grade [Ga]Ga-DOTA-CP04, a cholecystokinin-2 receptor agonist, using iPHASE MultiSyn synthesis platform. <i>EJNMMI Radiopharmacy and Chemistry</i> , <b>2019</b> , 4, 23	5.8	1
381	Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 228-228	2.2	6
380	The ProPSMA Study Clinical trial protocol: A prospective randomized multi-center study of the impact of Ga-68 PSMA PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS138-TPS138	2.2	1
379	Access to diagnostics and treatment of neuroendocrine tumors (NETs): The difference between patient perception and reality. <b>2019</b> , 5, 6-6		1
378	A randomized trial comparing fluorocholine-PET/CT with conventional imaging in prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2-2	2.2	
377	Access to diagnostics and treatment of neuroendocrine tumors (NETs): The difference between patient perception and reality.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e13524-e13524	2.2	
376	Clinical and FDG-PET markers of immune checkpoint inhibitor (ICI) response in patients with metastatic Merkel cell carcinoma (mMCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 9540-9540	2.2	
375	Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study. <i>Blood</i> , <b>2019</b> , 134, 3999-3999	2.2	2
374	Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. <i>European Urology Oncology</i> , <b>2019</b> , 2, 152-162	6.7	19
373	Radiosynthesis and preliminary in vivo evaluation of 18F-labelled glycosylated duramycin peptides for imaging of phosphatidylethanolamine during apoptosis. <i>MedChemComm</i> , <b>2019</b> , 10, 1930-1934	5	1
372	Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease. <i>Neurotherapeutics</i> , <b>2019</b> , 16, 192-202	6.4	34
371	Metabolic patterns and seizure outcomes following anterior temporal lobectomy. <i>Annals of Neurology</i> , <b>2019</b> , 85, 241-250	9.4	16
370	An International Survey on Clinical Reporting of PET/CT Examinations: A Starting Point for Cross-Specialty Engagement. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 480-485	8.9	3
369	PET/CT Lung Ventilation and Perfusion Scanning using Galligas and Gallium-68-MAA. <i>Seminars in Nuclear Medicine</i> , <b>2019</b> , 49, 71-81	5.4	25

368	Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 777-785	8.9	57
367	Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 718-727	8.8	7
366	Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework. <i>BJU International</i> , <b>2019</b> , 123, 1020-1030	5.6	7
365	FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 238-250	8.8	130
364	Dosimetry of Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 517-523	8.9	144
363	Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologists. <i>Internal Medicine Journal</i> , <b>2019</b> , 49, 615-621	1.6	4
362	Complementary role of MRI and positron emission tomography in diagnosing cerebral abscess in a patient with metastatic paraganglioma. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2018</b> , 62, 525	1.7	1
361	The Injustice of Being Judged by the Errors of Others: The Tragic Tale of the Battle for PET Reimbursement. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 418-420	8.9	2
360	Diagnostic challenges in a patient with an occult insulinoma:Ga-DOTA-exendin-4 PET/CT and Ga-DOTATATE PET/CT. <i>Clinical Case Reports (discontinued)</i> , <b>2018</b> , 6, 719-722	0.7	9
359	Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 62, 417-427	4.3	4
358	Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imaging. <i>Internal Medicine Journal</i> , <b>2018</b> , 48, 97-98	1.6	3
357	Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance. <i>International Journal of Cancer</i> , <b>2018</b> , 142, 2139-2152	7.5	41
356	Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. <i>Radiographics</i> , <b>2018</b> , 38, 200-217	5.4	152
355	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1211-1223	59.2	226
354	F-FDG-Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 749-755	8.9	23
353	Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 625-631	8.9	50
352	structural rearrangements in metastatic pheochromocytomas. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, 1-9	5.7	35
351	Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 262-277	8.8	62



350	Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5873-5882	12.9	35
349	[Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer - Author's reply. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, e373	21.7	9
348	Deep Learning Renal Segmentation for Fully Automated Radiation Dose Estimation in Unsealed Source Therapy. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 215	5.3	51
347	A First-in-Human Study of Ga-Nanocolloid PET/CT Sentinel Lymph Node Imaging in Prostate Cancer Demonstrates Aberrant Lymphatic Drainage Pathways. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 1837-1842	8.9	9
346	[Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 825-833	21.7	545
345	Changes in biodistribution on Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression. <i>Cancer Imaging</i> , <b>2018</b> , 18, 3	5.6	27
344	A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. <i>BJU International</i> , <b>2018</b> , 122, 783-793	5.6	67
343	Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5040-5040	2.2	1
342	Automated preparation of 2-[ F]fluoropropionate labeled peptides using a flexible, multi-stage synthesis platform (iPHASE Flexlab). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2018</b> , 61, 61-67	1.9	4
341	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. <i>European Journal of Cancer</i> , <b>2018</b> , 105, 88-102	7.5	37
340	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, e696-e708	21.7	59
339	Bayesian approach to determining penetrance of pathogenic SDH variants. <i>Journal of Medical Genetics</i> , <b>2018</b> , 55, 729-734	5.8	29
338	FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1733-1742	8.9	79
337	A new model for training in hybrid imaging. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1152-1154	21.7	2
336	THYROPET Study: Is It Biology or Technology That Is the Issue?. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 354	8.9	3
335	Citius, Altius, Fortius: An Olympian Dream for Theranostics. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 194-195	8.9	7
334	The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review. <i>Oncologist</i> , <b>2017</b> , 22, 272-285	5.7	14
333	Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. <i>Haematologica</i> , <b>2017</b> , 102, 356-363	6.6	40

332	Sulfonation of Tyrosine as a Method To Improve Biodistribution of Peptide-Based Radiotracers: Novel F-Labeled Cyclic RGD Analogues. <i>Molecular Pharmaceutics</i> , <b>2017</b> , 14, 1169-1180	5.6	6
331	Molecular imaging in the investigation of hypoglycaemic syndromes and their management. <i>Endocrine-Related Cancer</i> , <b>2017</b> , 24, R203-R221	5.7	23
330	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. <i>Neuroendocrinology</i> , <b>2017</b> , 105, 295-309	5.6	142
329	Wet or Dry? Do Liquid Biopsy Techniques Compete with or Complement PET for Disease Monitoring in Oncology?. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 869-870	8.9	6
328	Enhancing PET Signal at Target Tissue in Vivo: Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for Molecular Imaging of Integrin Expression with Gallium-68. <i>Bioconjugate Chemistry</i> , <b>2017</b> , 28, 481-495	6.3	24
327	Acute radiation oesophagitis associated with 2-deoxy-2-[18F]fluoro-d-glucose uptake on positron emission tomography/CT during chemo-radiation therapy in patients with non-small-cell lung cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2017</b> , 61, 682-688	1.7	4
326	Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 1622-1635	8.8	59
325	Detection of Synchronous Primary Malignancies with Ga-Labeled Prostate-Specific Membrane Antigen PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1938-1942	8.9	22
324	Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 3278-3287	5.6	91
323	Learning from Failure; Hypoxia Is an Evil Foe. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1043-1044	8.9	4
322	Follow up results of a prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. <i>Clinical and Translational Radiation Oncology</i> , <b>2017</b> , 2, 76-82	4.6	2
321	The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 67-77	8.8	84
320	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. <i>Neuroendocrinology</i> , <b>2017</b> , 105, 212-244	5.6	196
319	Cousins not twins: intratumoural and intertumoural heterogeneity in syndromic neuroendocrine tumours. <i>Journal of Pathology</i> , <b>2017</b> , 242, 273-283	9.4	6
318	Role of PET/CT in Melanoma <b>2017</b> , 37-51		
317	PET/CT in Melanoma (Additional Teaching Cases) <b>2017</b> , 53-63		
316	Automatic delineation of functional lung volumes with Ga-ventilation/perfusion PET/CT. <i>EJNMMI Research</i> , <b>2017</b> , 7, 82	3.6	14
315	Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer. <i>Cancer Imaging</i> , <b>2017</b> , 17, 31	5.6	14

314	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma.. <i>JCO Precision Oncology</i> , <b>2017</b> , 1, 1-14	3.6	25
313	Oligometastatic Renal Cell Carcinoma With Sarcomatoid Differentiation Demonstrating Variable Imaging Phenotypes on Ga-PSMA and F-FDG PET/CT: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	9
312	Seduction by Sensitivity: Reality, Illusion, or Delusion? The Challenge of Assessing Outcomes after PSMA Imaging Selection of Patients for Treatment. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1969-1971	8.9	12
311	Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 99, 947-955	4	23
310	EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program. <i>EJNMMI Physics</i> , <b>2017</b> , 4, 17	4.4	11
309	High clinical and morphologic response using Y-DOTA-octreotate sequenced with Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 476-489	8.8	36
308	Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9563-9563	2.2	1
307	[ <sup>18</sup> F]Fluoro Azomycin Arabinoside ([ <sup>18</sup> F]FAZA): Synthesis, Radiofluorination and Preliminary PET Imaging of Murine A431 Tumors. <i>Current Radiopharmaceuticals</i> , <b>2017</b> , 10, 93-101	1.8	1
306	New Tris(hydroxypyridinone) Bifunctional Chelators Containing Isothiocyanate Groups Provide a Versatile Platform for Rapid One-Step Labeling and PET Imaging with ( <sup>68</sup> Ga(3.)). <i>Bioconjugate Chemistry</i> , <b>2016</b> , 27, 309-18	6.3	47
305	Gallium-68 EDTA PET/CT for Renal Imaging. <i>Seminars in Nuclear Medicine</i> , <b>2016</b> , 46, 448-61	5.4	19
304	A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies. <i>Chemical Communications</i> , <b>2016</b> , 52, 11889-11892	5.8	59
303	Intense focal pituitary FDG uptake due to intravascular large B-cell lymphoma in pyrexia of unknown origin. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 1167-1168	7.1	2
302	A New Theranostic Paradigm for Advanced Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 1493-1494	1.9	8
301	How We Read Oncologic FDG PET/CT. <i>Cancer Imaging</i> , <b>2016</b> , 16, 35	5.6	46
300	Gallium-68 perfusion positron emission tomography/computed tomography to assess pulmonary function in lung cancer patients undergoing surgery. <i>Cancer Imaging</i> , <b>2016</b> , 16, 24	5.6	17
299	Does PET SUV Harmonization Affect PERCIST Response Classification?. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 1699-1706	8.9	26
298	Cancer Imaging reviewer acknowledgement 2015. <i>Cancer Imaging</i> , <b>2016</b> , 16,	5.6	78
297	Myeloid neoplasms after chemotherapy and PRRT: myth and reality. <i>Endocrine-Related Cancer</i> , <b>2016</b> , 23, C1-7	5.7	31

296	Ga-68 MAA Perfusion 4D-PET/CT Scanning Allows for Functional Lung Avoidance Using Conformal Radiation Therapy Planning. <i>Technology in Cancer Research and Treatment</i> , <b>2016</b> , 15, 114-21	2.7	26
295	'Hot spot' cardiac ischemia imaging with fluorodeoxyglucose positron emission tomography. <i>Journal of Nuclear Cardiology</i> , <b>2016</b> , 23, 1514-1517	2.1	1
294	Quantitative and qualitative analysis of [(18)F]FDG and [(18)F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 617-25	8.8	20
293	Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 1034-43	5.6	26
292	Strand breakage by decay of DNA-bound I provides a basis for combined PET imaging and Auger endoradiotherapy. <i>International Journal of Radiation Biology</i> , <b>2016</b> , 92, 686-697	2.9	4
291	Incremental diagnostic utility of gastric distension FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 644-53	8.8	9
290	Back to the Future: Nuclear Medicine Rediscovered Its Therapeutic Roots <b>2016</b> , 277-287		1
289	Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription. <i>Oncotarget</i> , <b>2016</b> , 7, 48887-48904	3.3	7
288	Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2016</b> , 38, 87-96	1.2	79
287	A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 54, 223-32	4.3	38
286	(68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. <i>Cancer Imaging</i> , <b>2016</b> , 16, 22	5.6	102
285	Short and long-term prognostic implications of a low embolic burden in oncology patients diagnosed with symptomatic pulmonary embolism. <i>Annals of Hematology</i> , <b>2016</b> , 95, 651-2	3	1
284	Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYC <sup>N</sup> neuroblastoma mouse model. <i>International Journal of Cancer</i> , <b>2016</b> , 139, 194-204	7.5	21
283	Recent developments in radiolabelled peptides for PET imaging of cancer. <i>Tetrahedron Letters</i> , <b>2016</b> , 57, 4119-4127	2	16
282	Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 176-85	8.8	68
281	The genomic landscape of pheochromocytoma. <i>Journal of Pathology</i> , <b>2015</b> , 236, 78-89	9.4	51
280	Synthesis and in Vivo Evaluation of [123I]Melanin-Targeted Agents. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 6214-24	8.3	5
279	Distribution Atlas of Proliferating Bone Marrow in Non-Small Cell Lung Cancer Patients Measured by FLT-PET/CT Imaging, With Potential Applicability in Radiation Therapy Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 92, 1035-1043	4	24

278	Pulmonary Scintigraphy for the Diagnosis of Acute Pulmonary Embolism: A Survey of Current Practices in Australia, Canada, and France. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 1212-7	8.9	26
277	High-resolution pulmonary ventilation and perfusion PET/CT allows for functionally adapted intensity modulated radiotherapy in lung cancer. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 115, 157-62	5.3	57
276	Moving Beyond "Lumpology": PET/CT Imaging of Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3815-7	12.9	18
275	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. <i>Blood</i> , <b>2015</b> , 125, 3679-87	2.2	190
274	The evolving role of molecular imaging in non-small cell lung cancer radiotherapy. <i>Seminars in Radiation Oncology</i> , <b>2015</b> , 25, 133-42	5.5	4
273	Lung cancer. <i>PET Clinics</i> , <b>2015</b> , 10, 147-58	2.2	8
272	Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 523-9	8.9	30
271	Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT). <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 968-9	8.9	12
270	Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 2072-82	8.8	68
269	Re: palliative bypass for small bowel carcinoid with mesenteric mass and vascular encasement. <i>ANZ Journal of Surgery</i> , <b>2015</b> , 85, 197	1	1
268	Analysis of 177Lu-DOTA-octreotate therapy-induced DNA damage in peripheral blood lymphocytes of patients with neuroendocrine tumors. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 505-11	8.9	36
267	<sup>18</sup> F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 1825-32	8.8	17
266	Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. <i>Lancet Haematology</i> , <b>2015</b> , 2, e445-55	14.6	54
265	Accuracy and Utility of Deformable Image Registration in (68)Ga 4D PET/CT Assessment of Pulmonary Perfusion Changes During and After Lung Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 93, 196-204	4	16
264	15-Year Experience of 18F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 1328-33	8.9	21
263	Correlation of 68Ga Ventilation-Perfusion PET/CT with Pulmonary Function Test Indices for Assessing Lung Function. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 1718-23	8.9	20
262	Ventilation/Perfusion Positron Emission Tomography--Based Assessment of Radiation Injury to Lung. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 93, 408-17	4	30
261	Rapid kit-based (68)Ga-labelling and PET imaging with THP-Tyr(3)-octreotate: a preliminary comparison with DOTA-Tyr(3)-octreotate. <i>EJNMMI Research</i> , <b>2015</b> , 5, 52	3.6	35

260	Bifunctional (64)Cu-labelled macrobicyclic cage amine isothiocyanates for immuno-positron emission tomography. <i>Dalton Transactions</i> , <b>2015</b> , 44, 4901-9	4.3	22
259	Regulation of rDNA transcription in response to growth factors, nutrients and energy. <i>Gene</i> , <b>2015</b> , 556, 27-34	3.8	65
258	Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 25-32	8.8	14
257	Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1112-5	8.9	8
256	Longitudinal Partial Volume Correction in 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Studies of Alzheimer Disease. <i>Journal of Computer Assisted Tomography</i> , <b>2015</b> , 39, 559-64	2.2	1
255	The role of positron emission tomography/computed tomography in planning radiotherapy in endometrial cancer. <i>International Journal of Gynecological Cancer</i> , <b>2015</b> , 25, 645-9	3.5	8
254	Applying Advanced Imaging Techniques to a Murine Model of Orthotopic Osteosarcoma. <i>Frontiers in Surgery</i> , <b>2015</b> , 2, 36	2.3	4
253	Respiratory-gated (4D) FDG-PET detects tumour and normal lung response after stereotactic radiotherapy for pulmonary metastases. <i>Acta Oncologica</i> , <b>2015</b> , 54, 1105-12	3.2	11
252	Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. <i>Radiographics</i> , <b>2015</b> , 35, 500-16	5.4	309
251	Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1221-3	2.2	3
250	Reply to G. Keramida et al. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4121-2	2.2	1
249	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. <i>Cancer Research</i> , <b>2015</b> , 75, 5228-34	10.1	196
248	Statistically Assigned Response Criteria in Solid Tumors (STARCIST). <i>Cancer Imaging</i> , <b>2015</b> , 15, 9	5.6	3
247	68Ga-EDTA PET/CT imaging and plasma clearance for glomerular filtration rate quantification: comparison to conventional 51Cr-EDTA. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 405-9	8.9	25
246	Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group	2.2	6
245	Spleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy. <i>PLoS ONE</i> , <b>2015</b> , 10, e0142608	3.7	15
244	Postchemotherapy and tumor-selective targeting with the La-specific DAB4 monoclonal antibody relates to apoptotic cell clearance. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 772-9	8.9	15
243	Enhanced white adipose tissue metabolism in iatrogenic Cushing's syndrome with FDG PET/CT. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 3041-2	5.6	10

242	PET imaging of tumours with a <sup>64</sup> Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate. <i>Dalton Transactions</i> , <b>2014</b> , 43, 1386-96	4.3	69
241	Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. <i>Cancer Discovery</i> , <b>2014</b> , 4, 423-33	24.4	180
240	A prospective investigation into the clinical impact of 4D-PET/CT in the characterisation of solitary pulmonary nodules. <i>Cancer Imaging</i> , <b>2014</b> , 14, 24	5.6	14
239	Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3048-58	2.2	927
238	Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2014</b> , 41, 1831-44	8.8	60
237	The utility of <sup>18</sup> F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification. <i>Cancer Imaging</i> , <b>2014</b> , 14, 13	5.6	27
236	Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by ( <sup>18</sup> F)-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 1075-80	8.9	22
235	Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901. <i>Nuclear Medicine and Biology</i> , <b>2014</b> , 41, 148-54	2.1	10
234	Differential ( <sup>18</sup> F)-FDG and ( <sup>18</sup> F)-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 1069-74	8.9	60
233	In vivo measurement of hippocampal GABAA/cBZR density with [ <sup>18</sup> F]-flumazenil PET for the study of disease progression in an animal model of temporal lobe epilepsy. <i>PLoS ONE</i> , <b>2014</b> , 9, e86722	3.7	17
232	Association between radiation pneumonitis and tumor response in patients with NSCLC treated with chemoradiation. <i>Radiation Oncology</i> , <b>2014</b> , 9, 217	4.2	2
231	Geographic miss of lung tumours due to respiratory motion: a comparison of 3D vs 4D PET/CT defined target volumes. <i>Radiation Oncology</i> , <b>2014</b> , 9, 291	4.2	26
230	A prospective observational study of Gallium-68 ventilation and perfusion PET/CT during and after radiotherapy in patients with non-small cell lung cancer. <i>BMC Cancer</i> , <b>2014</b> , 14, 740	4.8	22
229	The customer is always right, even when you are justifiably wrong. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 1923-4	8.9	5
228	Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using <sup>18</sup> F-fluorodeoxyglucose positron emission tomography/computed tomography imaging. <i>Oncologist</i> , <b>2014</b> , 19, 175-6	5.7	19
227	Correlation of p16 status, hypoxic imaging using [ <sup>18</sup> F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2014</b> , 58, 89-97	1.7	28
226	Vacuum immobilisation reduces tumour excursion and minimises intrafraction error in a cohort study of stereotactic ablative body radiotherapy for pulmonary metastases. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2014</b> , 58, 244-52	1.7	14
225	Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. <i>Melanoma Research</i> , <b>2014</b> , 24, 504-8	3.3	56

224	Absence of a relationship between tumor $^{18}$ F-fluorodeoxyglucose standardized uptake value and survival in patients treated with definitive radiotherapy for non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 377-82	8.9	15
223	Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour. <i>Clinical Endocrinology</i> , <b>2014</b> , 81, 940-2	3.4	10
222	. <i>Clinical and Translational Imaging</i> , <b>2014</b> , 2, 5-12	2	1
221	High-resolution imaging of pulmonary ventilation and perfusion with $^{68}$ Ga-VQ respiratory gated (4-D) PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2014</b> , 41, 343-9	8.8	34
220	Validating and improving CT ventilation imaging by correlating with ventilation 4D-PET/CT using $^{68}$ Ga-labeled nanoparticles. <i>Medical Physics</i> , <b>2014</b> , 41, 011910	4.4	62
219	Segmental hyperperfusion in lobar pneumonia visualized with respiratory-gated four-dimensional pulmonary perfusion positron emission tomography-computed tomography. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2014</b> , 189, 104-5	10.2	4
218	Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9006-9006	2.2	2
217	Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice. <i>PLoS ONE</i> , <b>2014</b> , 9, e95847	3.7	10
216	Rapid blood clearance and lack of long-term renal toxicity of $^{177}$ Lu-DOTATATE enables shortening of renoprotective amino acid infusion. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2013</b> , 40, 1853-60	8.8	27
215	High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2013</b> , 40, 1330-6	8.8	14
214	The impact of time between staging PET/CT and definitive chemo-radiation on target volumes and survival in patients with non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 106, 288-91	5.3	40
213	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 3936-44	7.5	63
212	Imaging of hypoxia with $^{18}$ F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2013</b> , 57, 475-81	1.7	48
211	Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 687-94	5.6	87
210	The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: results of a prospective study with mature survival data. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 106, 292-8	5.3	46
209	A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma. <i>Oral Oncology</i> , <b>2013</b> , 49, 468-74	4.4	23
208	Validation of a 4D-PET maximum intensity projection for delineation of an internal target volume. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 86, 749-54	4	29
207	Can structural or functional changes following traumatic brain injury in the rat predict epileptic outcome?. <i>Epilepsia</i> , <b>2013</b> , 54, 1240-50	6.4	97



206	18F-flumazenil: a $\beta$ -aminobutyric acid A-specific PET radiotracer for the localization of drug-resistant temporal lobe epilepsy. <i>Journal of Nuclear Medicine</i> , <b>2013</b> , 54, 1270-7	8.9	45
205	18F-FDG PET provides high-impact and powerful prognostic stratification in the staging of Merkel cell carcinoma: a 15-year institutional experience. <i>Journal of Nuclear Medicine</i> , <b>2013</b> , 54, 1223-9	8.9	65
204	Not-so-random errors: randomized controlled trials are not the only evidence of the value of PET--rebuttal. <i>Journal of Nuclear Medicine</i> , <b>2013</b> , 54, 492	8.9	1
203	Treatment response in the neck: p16+ versus p16- oropharyngeal cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2013</b> , 57, 364-72	1.7	16
202	One-step radiosynthesis of 4-nitrophenyl 2-[(18 F)fluoropropionate ([18 F]NFP); improved preparation of radiolabeled peptides for PET imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2013</b> , 56, 726-30	1.9	14
201	Let's get SEERious: more accurate staging with consequent high management impact is not just stage migration. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 819	2.2	4
200	Abscopal [corrected] effects after conventional and stereotactic lung irradiation of non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, e71-2	8.9	68
199	Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions. <i>Nuclear Medicine Communications</i> , <b>2013</b> , 34, 521-6	1.6	5
198	An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging. <i>Medical Physics</i> , <b>2013</b> , 40, 112503	4.4	52
197	Hypometabolism precedes limbic atrophy and spontaneous recurrent seizures in a rat model of TLE. <i>Epilepsia</i> , <b>2012</b> , 53, 1233-44	6.4	73
196	High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2012</b> , 56, 40-7	1.7	183
195	The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39, 50-6	8.8	90
194	Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on diagnosis and antimicrobial utilization in patients with high-risk febrile neutropenia. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 1889-95	1.9	18
193	Tumour targeting of Auger emitters using DNA ligands conjugated to octreotate. <i>International Journal of Radiation Biology</i> , <b>2012</b> , 88, 1009-18	2.9	8
192	Is there still a role for SPECT-CT in oncology in the PET-CT era?. <i>Nature Reviews Clinical Oncology</i> , <b>2012</b> , 9, 712-20	19.4	106
191	Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2391-401	12.9	331
190	The role of positron emission tomography/computed tomography in radiation therapy planning for patients with lung cancer. <i>Seminars in Nuclear Medicine</i> , <b>2012</b> , 42, 308-19	5.4	35
189	The motivations and methodology for high-throughput PET imaging of small animals in cancer research. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39, 1497-509	8.8	13

188	Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies. <i>EJNMMI Research</i> , <b>2012</b> , 2, 31	3.6	7
187	Should positron emission tomography/computed tomography be the first rather than the last test performed in the assessment of cancer?. <i>Cancer Imaging</i> , <b>2012</b> , 12, 315-23	5.6	13
186	Preclinical characterization of 18F-D-FPHCys, a new amino acid-based PET tracer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39, 703-12	8.8	5
185	Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39, 1348-55	8.8	24
184	Sex and SUVmax: sex-dependent prognostication in early non-small cell lung cancer. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 1676-85	8.9	7
183	Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1798-807	12.9	46
182	Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1527-33	3.2	173
181	Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 1007-15	8.9	61
180	18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 530-7	8.9	28
179	18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 864-71	8.9	82
178	Not-so-random errors: randomized controlled trials are not the only evidence of the value of PET. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 1820-2; author reply 1822-1824	8.9	4
177	Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1628-34	2.2	141
176	Scatter limitation to correct for arm movement in PET/CT. <i>Clinical Nuclear Medicine</i> , <b>2012</b> , 37, 786-7	1.7	4
175	Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer. <i>Clinical Nuclear Medicine</i> , <b>2012</b> , 37, 971-6	1.7	47
174	An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 553-7	15.9	144
173	Breast Cancer: Role of Planar, SPECT and PET in Imaging Bone Metastases <b>2012</b> , 661-689		
172	Changing paradigms with molecular imaging of neuroendocrine tumors. <i>Discovery Medicine</i> , <b>2012</b> , 14, 71-81	2.5	48
171	68Ga PET/CT ventilation-perfusion imaging for pulmonary embolism: a pilot study with comparison to conventional scintigraphy. <i>Journal of Nuclear Medicine</i> , <b>2011</b> , 52, 1513-9	8.9	73

170	Imaging in follicular NHL. <i>Best Practice and Research in Clinical Haematology</i> , <b>2011</b> , 24, 165-77	4.2	14
169	Delivering affordable cancer care in high-income countries. <i>Lancet Oncology</i> , <b>2011</b> , 12, 933-80	21.7	476
168	Imaging, radiation oncology and randomised trials: time for a change?. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2011</b> , 55, 97-100	1.7	2
167	Gallium-68 complex of a macrobicyclic cage amine chelator tethered to two integrin-targeting peptides for diagnostic tumor imaging. <i>Bioconjugate Chemistry</i> , <b>2011</b> , 22, 2093-103	6.3	46
166	Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. <i>Cancer Imaging</i> , <b>2011</b> , 11, 56-66	5.6	92
165	PET and PET/CT in Treatment Planning. <i>Medical Radiology</i> , <b>2011</b> , 173-186	0.2	
164	White fat, factitious hyperglycemia, and the role of FDG PET to enhance understanding of adipocyte metabolism. <i>EJNMMI Research</i> , <b>2011</b> , 1, 2	3.6	7
163	A dual radiologic contrast agent protocol for 18F-FDG and 18F-FLT PET/CT imaging of mice bearing abdominal tumors. <i>Molecular Imaging and Biology</i> , <b>2011</b> , 13, 518-525	3.8	4
162	Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2011</b> , 38, 642-50	8.8	26
161	18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different. <i>Skeletal Radiology</i> , <b>2011</b> , 40, 1007-15	2.7	53
160	Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. <i>Cancer</i> , <b>2011</b> , 117, 3981-8	6.4	48
159	Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 80, 1365-71	4	45
158	Radiosynthesis and biological evaluation of L- and D-S-(3-[18F]fluoropropyl)homocysteine for tumor imaging using positron emission tomography. <i>Journal of Medicinal Chemistry</i> , <b>2011</b> , 54, 1860-70	8.3	21
157	In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer. <i>Molecular Cancer Therapeutics</i> , <b>2011</b> , 10, 1440-9	6.1	66
156	Positron emission tomography and neoadjuvant therapy of breast cancer. <i>Journal of the National Cancer Institute Monographs</i> , <b>2011</b> , 2011, 111-5	4.8	5
155	Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-[2-(diethylamino)ethyl]pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration. <i>Journal of Nuclear Medicine</i> , <b>2011</b> , 52, 115-22	8.9	28
154	Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models. <i>Journal of Nuclear Medicine</i> , <b>2011</b> , 52, 1261-7	8.9	28
153	Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3304-15	12.9	111

152	Pretreatment transcriptional profiling for predicting response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3039-47	12.9	40
151	Doing more harm than good? Do systematic reviews of PET by health technology assessment agencies provide an appraisal of the evidence that is closer to the truth than the primary data supporting its use?. <i>Journal of Nuclear Medicine</i> , <b>2011</b> , 52 Suppl 2, 64S-73S	8.9	16
150	The clinical significance and management of lesion motion due to respiration during PET/CT scanning. <i>Cancer Imaging</i> , <b>2011</b> , 11, 224-36	5.6	17
149	Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. <i>Medical Journal of Australia</i> , <b>2010</b> , 193, 46-52	4	74
148	Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. <i>Cancer Imaging</i> , <b>2010</b> , 10 Spec no A, S83-91	5.6	54
147	Restaging: should we persist without pattern recognition?. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 1830-28.9		6
146	Progressive metabolic and structural cerebral perturbations after traumatic brain injury: an in vivo imaging study in the rat. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 1788-95	8.9	59
145	High-contrast PET of melanoma using (18)F-MEL050, a selective probe for melanin with predominantly renal clearance. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 441-7	8.9	47
144	Are health economics making us sick?. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 1665-7	8.9	6
143	90Y-edotreotide for metastatic carcinoid refractory to octreotide. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1652-9	2.2	256
142	18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 1559-64	8.9	46
141	The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51 Suppl 1, 28-33	1.9	21
140	Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. <i>Journal of Clinical Neuroscience</i> , <b>2010</b> , 17, 43-9	2.2	59
139	Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2010</b> , 54, 325-32	1.7	52
138	How can we tell if PET imaging for cancer is cost effective?. <i>Lancet Oncology</i> , <b>2010</b> , 11, 711-2	21.7	9
137	Using positron emission tomography to assess tumor proliferation in non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51, 183-5	1.9	2
136	Phase 1 study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer. <i>International Journal of Gynecological Cancer</i> , <b>2010</b> , 20, 827-33	3.5	25
135	High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2010</b> , 37, 991-1001	8.8	28

134	177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2010</b> , 37, 1869-75	8.8	50
133	Breast lymphatic drainage via the pulmonary lymphatic system. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2010</b> , 37, 2203	8.8	3
132	Reproducibility of "intelligent" contouring of gross tumor volume in non-small-cell lung cancer on PET/CT images using a standardized visual method. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 77, 1151-7	4	53
131	High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer. <i>Cancer</i> , <b>2010</b> , 116, 5030-7	6.4	61
130	EEG dipole source localization of interictal spikes in non-lesional TLE with and without hippocampal sclerosis. <i>Epilepsy Research</i> , <b>2010</b> , 92, 183-90	3	11
129	Incidental findings on follow-up fluorodeoxyglucose positron emission tomography studies in lymphoma patients: beware the outlier. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 865-7	1.9	
128	High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2009</b> , 24, 527-33	3.9	37
127	Lamina-specific changes in hippocampal GABA(A)/cBZR and mossy fibre sprouting during and following amygdala kindling in the rat. <i>Neurobiology of Disease</i> , <b>2009</b> , 35, 337-47	7.5	11
126	The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. <i>Gynecologic Oncology</i> , <b>2009</b> , 112, 462-8	4.9	109
125	The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project: Response to a letter from Dr. Maurie Markman. <i>Gynecologic Oncology</i> , <b>2009</b> , 114, 536-537	4.9	
124	Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2009</b> , 36, 347-53	8.8	29
123	PET/MRI: a different spin from under the rim. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2009</b> , 36 Suppl 1, S10-4	8.8	17
122	In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2009</b> , 36, 958-65	8.8	19
121	The risk of exaggerated risk aversion-a life and death struggle for molecular imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2009</b> , 36, 1693-4	8.8	6
120	The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. <i>British Journal of Cancer</i> , <b>2009</b> , 100, 693-700	8.7	93
119	Radiation changes do not interfere with postchemoradiation restaging of patients with rectal cancer by FDG PET/CT before curative surgical therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 60-6	4	29
118	Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 740-6	4	52
117	Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 75, 1098-104	4	84

116	Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. <i>Journal of Nuclear Medicine</i> , <b>2009</b> , 50 Suppl 1, 31S-42S	8.9	121
115	Discovery of [18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance. <i>Journal of Medicinal Chemistry</i> , <b>2009</b> , 52, 5299-302	8.3	45
114	Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009. <i>Lancet Oncology</i> , <b>2009</b> , 10, 1086-92	21.7	45
113	Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by positron emission tomography and treated with curative intent. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19, 912-8	3.5	62
112	[18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. <i>Clinical Lymphoma and Myeloma</i> , <b>2008</b> , 8, 159-65		35
111	Role of functional imaging in head and neck squamous cell carcinoma: fluorodeoxyglucose positron emission tomography and beyond. <i>Hematology/Oncology Clinics of North America</i> , <b>2008</b> , 22, 1221-38, ix-x	3.1	9
110	PET for Therapeutic Response Monitoring in Oncology. <i>PET Clinics</i> , <b>2008</b> , 3, 89-99	2.2	3
109	Time and again, children resemble their parents. <i>Journal of Nuclear Medicine</i> , <b>2008</b> , 49, 1577-8	8.9	1
108	The cost-effective use of 18F-FDG PET in the presurgical evaluation of medically refractory focal epilepsy. <i>Journal of Nuclear Medicine</i> , <b>2008</b> , 49, 931-7	8.9	59
107	PET for sarcomas other than gastrointestinal stromal tumors. <i>Oncologist</i> , <b>2008</b> , 13 Suppl 2, 22-6	5.7	27
106	What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 1653-6	1.9	5
105	The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas. <i>Expert Review of Molecular Diagnostics</i> , <b>2008</b> , 8, 105-19	3.8	6
104	A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy. <i>Haematologica</i> , <b>2008</b> , 93, 789-90	6.6	6
103	In vivo tracking of dendritic cells in patients with multiple myeloma. <i>Journal of Immunotherapy</i> , <b>2008</b> , 31, 166-79	5	34
102	Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. <i>Anti-Cancer Drugs</i> , <b>2008</b> , 19, 547-52	2.4	42
101	The role of PET-CT in the management of patients with advanced cancer of the head and neck. <i>Current Oncology Reports</i> , <b>2008</b> , 10, 149-55	6.3	16
100	The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 72, 1298-306	4	37
99	Impact of [18F] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 71, 213-9	4	99

98	In Reply to Dr. Faraci and Colleagues. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 72, 304		4
97	Non-small Cell Lung Carcinoma <b>2008</b> , 237-247		
96	The extent of resection of FDG-PET hypometabolism relates to outcome of temporal lobectomy. <i>Brain</i> , <b>2007</b> , 130, 548-60	11.2	86
95	Overview of early response assessment in lymphoma with FDG-PET. <i>Cancer Imaging</i> , <b>2007</b> , 7, 10-8	5.6	66
94	Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. <i>Head and Neck</i> , <b>2007</b> , 29, 986-95	4.2	119
93	How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT?. <i>Cancer</i> , <b>2007</b> , 109, 117-24	6.4	56
92	Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 69, S61-3	4	31
91	Imaging in the diagnosis and treatment of non-small cell lung cancer. <i>Respirology</i> , <b>2007</b> , 12, 165-72	3.6	24
90	'MRI-negative PET-positive' temporal lobe epilepsy (TLE) and mesial TLE differ with quantitative MRI and PET: a case control study. <i>BMC Neurology</i> , <b>2007</b> , 7, 16	3.1	35
89	Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 571-8	2.2	1113
88	The SUV and FLT PET: a tasty alphabet soup or a dog's breakfast?. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 649-52	1.9	3
87	Atypical brown fat distribution in young males demonstrated on PET/CT. <i>Clinical Nuclear Medicine</i> , <b>2007</b> , 32, 679-82	1.7	19
86	Impact of PET on radiation therapy planning in lung cancer. <i>Radiologic Clinics of North America</i> , <b>2007</b> , 45, 627-38, v	2.3	13
85	Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 596-600	1.9	24
84	Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , <b>2007</b> , 10, 203-11	3.4	84
83	Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2006</b> , 33, 759-69	8.8	57
82	Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2006</b> , 33, 441-52	8.8	36
81	FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2006</b> , 33, 770-8	8.8	49

80	The impact of PET/CT in the management of recurrent ovarian cancer. <i>Gynecologic Oncology</i> , <b>2006</b> , 103, 271-6	4.9	110
79	Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 3026-31	2.2	76
78	Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 2098-104	2.2	471
77	Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 4418-25	2.2	72
76	Ga-67 SPECT: ave atque vale! Or have we bid a premature farewell to a trusted friend?. <i>Leukemia and Lymphoma</i> , <b>2006</b> , 47, 2440-2	1.9	6
75	The evolving role of fluorodeoxyglucose positron emission tomography (FDG PET) in lymphoma: how do we reconcile conflicting results in the era of evidence-based medicine?. <i>Leukemia and Lymphoma</i> , <b>2006</b> , 47, 2008-10	1.9	5
74	A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. <i>Radiotherapy and Oncology</i> , <b>2006</b> , 78, 254-61	5.3	151
73	Impact of PET on Radiation Therapy Planning. <i>PET Clinics</i> , <b>2006</b> , 1, 317-28	2.2	1
72	PET/CT: will it change the way that we use CT in cancer imaging?. <i>Cancer Imaging</i> , <b>2006</b> , 6, S52-62	5.6	35
71	PET tracer development--a tale of mice and men. <i>Cancer Imaging</i> , <b>2006</b> , 6, S102-6	5.6	11
70	Role of PET-CT in the Optimization of Thoracic Radiotherapy. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 81-88.9		3
69	Depression in temporal lobe epilepsy surgery patients: an FDG-PET study. <i>Epilepsia</i> , <b>2006</b> , 47, 2125-30	6.4	70
68	Role of PET-CT in the Optimization of Thoracic Radiotherapy. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 81-88.9		10
67	Primary Bone Tumors <b>2006</b> , 267-301		1
66	Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. <i>Journal of Nuclear Medicine</i> , <b>2006</b> , 47, 14-22	8.9	97
65	Role of PET-CT in the optimization of thoracic radiotherapy. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 81-4	8.9	4
64	Initial staging of lymphoma with positron emission tomography and computed tomography. <i>Seminars in Nuclear Medicine</i> , <b>2005</b> , 35, 165-75	5.4	67
63	PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy. <i>Lung Cancer</i> , <b>2005</b> , 47, 49-57	5.9	18



62	Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. <i>Lung Cancer</i> , <b>2005</b> , 49, 95-108	5.9	145
61	The role of PET in monitoring therapy. <i>Cancer Imaging</i> , <b>2005</b> , 5, 51-7	5.6	39
60	Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. <i>Head and Neck</i> , <b>2005</b> , 27, 175-81	4.2	193
59	Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2005</b> , 32, 1384-91	8.8	120
58	Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease: diagnostic dilemmas and management options. <i>Annals of Hematology</i> , <b>2005</b> , 84, 118-21	3	19
57	The utility of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in the investigation of patients with disseminated carcinoma of unknown primary origin. <i>Molecular Imaging and Biology</i> , <b>2005</b> , 7, 236-43	3.8	18
56	Functional imaging techniques for evaluation of sarcomas. <i>Cancer Imaging</i> , <b>2005</b> , 5, 58-65	5.6	29
55	Clinical applications of molecular imaging in sarcoma evaluation. <i>Cancer Imaging</i> , <b>2005</b> , 5, 66-72	5.6	36
54	Clinical experience with the first combined positron emission tomography/computed tomography scanner in Australia. <i>Medical Journal of Australia</i> , <b>2005</b> , 182, 172-6	4	10
53	PET Scanning in Staging and Evaluation of Response to Treatment in Lung Cancer <b>2005</b> , 461-471		
52	An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. <i>Cancer Research</i> , <b>2005</b> , 65, 9633-6	10.1	72
51	Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. <i>Molecular Cancer Therapeutics</i> , <b>2005</b> , 4, 1417-22	6.1	46
50	The role of thallium-201 and pentavalent dimercaptosuccinic acid for staging cartilaginous tumours. <i>International Seminars in Surgical Oncology</i> , <b>2004</b> , 1, 10		15
49	Does positron emission tomography change management in primary rectal cancer? A prospective assessment. <i>Diseases of the Colon and Rectum</i> , <b>2004</b> , 47, 451-8	3.1	88
48	Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2004</b> , 60, 412-8	4	151
47	Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , <b>2004</b> , 26, 1008-17	4.2	62
46	MRI-negative PET-positive temporal lobe epilepsy: a distinct surgically remediable syndrome. <i>Brain</i> , <b>2004</b> , 127, 2276-85	11.2	255
45	Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2004</b> , 27, 164-71	2.7	79

44	F-18 PET soft tissue uptake in seatbelt injury. <i>Clinical Nuclear Medicine</i> , <b>2004</b> , 29, 809-10	1.7	1
43	Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 1285-92	2.2	369
42	FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy--survival correlates with metastatic disease burden. <i>Acta Oncologica</i> , <b>2003</b> , 42, 48-54	3.2	37
41	The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor. <i>Head and Neck</i> , <b>2003</b> , 25, 138-45	4.2	62
40	PET scanning in lung cancer: current status and future directions. <i>Journal of Surgical Oncology</i> , <b>2003</b> , 21, 149-55		34
39	Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. <i>Clinical Lymphoma and Myeloma</i> , <b>2003</b> , 4, 43-9		68
38	Applications of positron emission tomography in the development of molecular targeted cancer therapeutics. <i>BioDrugs</i> , <b>2003</b> , 17, 339-54	7.9	16
37	Beyond FDG: novel PET tracers for cancer imaging. <i>Cancer Imaging</i> , <b>2003</b> , 4, 22-4	5.6	11
36	18F-FDG PET in candidates for radiation therapy: is it important and how do we validate its impact?. <i>Journal of Nuclear Medicine</i> , <b>2003</b> , 44, 30-2	8.9	17
35	Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2002</b> , 29, 506-15	8.8	23
34	Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2002</b> , 52, 351-61	4	66
33	Discordant response to chemotherapy detected by PET scanning: unveiling of a second primary cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2002</b> , 25, 368-70	2.7	9
32	Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. <i>Acta Oncologica</i> , <b>2002</b> , 41, 425-9	3.2	96
31	Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. <i>American Journal of Medicine</i> , <b>2002</b> , 112, 262-8	2.4	138
30	Inadvertent 2-deoxy-2-[18F]fluoro-D-glucose lymphoscintigraphy: a potential pitfall characterized by hybrid PET-CT. <i>Molecular Imaging and Biology</i> , <b>2002</b> , 4, 276-8	3.8	6
29	The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. <i>Journal of Nuclear Medicine</i> , <b>2002</b> , 43, 492-9	8.9	103
28	Imaging with F-18 FDG PET is superior to Tl-201 SPECT in the staging of non-small cell lung cancer for radical radiation therapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2001</b> , 45, 483-90		8
27	F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. <i>Cancer</i> , <b>2001</b> , 92, 886-95	6.4	195

26	High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2001</b> , 50, 287-93	4	245
25	Cardiac blood-pool imaging in oncology more than an ejection fraction?. <i>Clinical Nuclear Medicine</i> , <b>2001</b> , 26, 18-26	1.7	2
24	Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 535-42	2.2	170
23	Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 111-8	2.2	188
22	Positron emission tomography in pulmonary masses where tissue diagnosis is unhelpful or not possible. <i>Medical Journal of Australia</i> , <b>2001</b> , 175, 303-7	4	16
21	Differential effects of bisphosphonate on Paget's disease and metastatic prostatic carcinoma-bone scan findings. <i>Clinical Nuclear Medicine</i> , <b>2001</b> , 26, 347-8	1.7	9
20	Positron emission tomography (PET): experience with a large-field-of-view three-dimensional PET scanner. <i>Medical Journal of Australia</i> , <b>1999</b> , 171, 529-32	4	11
19	Simulated bone metastases: a case study of two patients with breast cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>1999</b> , 43, 365-8		2
18	Surgery for primary hyperparathyroidism 1962-1996: Indications and outcomes. <i>Medical Journal of Australia</i> , <b>1998</b> , 169, 118-119	4	1
17	Hiatus hernia: a potential cause of false-positive iodine-131 scan in thyroid carcinoma. <i>Clinical Nuclear Medicine</i> , <b>1998</b> , 23, 621-2	1.7	10
16	Nuclear medicine techniques provide unique physiologic characterization of suspected and known soft tissue and bone sarcomas. <i>Acta Orthopaedica</i> , <b>1997</b> , 273, 25-36		13
15	Radiosynthesis of [123I]N-methyl-4-iododexetimide and [123I]N-methyl-4-iodolevetimide: in vitro and in vivo characterisation of binding to muscarinic receptors in the rat heart. <i>Nuclear Medicine and Biology</i> , <b>1996</b> , 23, 147-53	2.1	9
14	Prediction of outcome after revascularization in patients with poor left ventricular function. <i>Annals of Thoracic Surgery</i> , <b>1996</b> , 61, 1428-34	2.7	37
13	Impact of complementary parathyroid scintigraphy and ultrasonography on the surgical management of hyperparathyroidism. <i>Surgery</i> , <b>1996</b> , 120, 845-51	3.6	28
12	Iodine-123 N-methyl-4-iododexetimide: a new radioligand for single-photon emission tomographic imaging of myocardial muscarinic receptors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>1995</b> , 22, 339-45		7
11	The effects of afterload reduction on myocardial carbon 11-labeled acetate kinetics and noninvasively estimated mechanical efficiency in patients with dilated cardiomyopathy. <i>Journal of Nuclear Cardiology</i> , <b>1994</b> , 1, 3-16	2.1	39
10	An approach to ventricular efficiency by use of carbon 11-labeled acetate and positron emission tomography. <i>Journal of Nuclear Cardiology</i> , <b>1994</b> , 1, 262-9	2.1	14
9	Metabolic imaging by positron emission tomography early after myocardial infarction as a predictor of recovery of myocardial function after reperfusion. <i>Journal of Nuclear Cardiology</i> , <b>1994</b> , 1, 124-37	2.1	12

8	Use of carbon-11 acetate and dynamic positron emission tomography to assess regional myocardial oxygen consumption in patients with acute myocardial infarction receiving thrombolysis or coronary angioplasty. <i>American Journal of Cardiology</i> , <b>1993</b> , 71, 529-35	3	18
7	Assessment of myocardial oxidative metabolism in aortic valve disease using positron emission tomography with C-11 acetate. <i>American Heart Journal</i> , <b>1992</b> , 123, 653-64	4.9	14
6	Assessment of right ventricular oxidative metabolism by positron emission tomography with C-11 acetate in aortic valve disease. <i>American Journal of Cardiology</i> , <b>1991</b> , 67, 753-7	3	13
5	Quantitative evaluation of regional substrate metabolism in the human heart by positron emission tomography. <i>Journal of the American College of Cardiology</i> , <b>1991</b> , 18, 101-11	15.1	72
4	Insulin-glucose clamp for standardization of metabolic conditions during F-18 fluoro-deoxyglucose pet imaging. <i>Journal of the American College of Cardiology</i> , <b>1991</b> , 17, A381	15.1	8
3	Positron emission tomography myocardial viability studies in patients with diabetes mellitus viability. <i>Journal of the American College of Cardiology</i> , <b>1991</b> , 17, A121	15.1	10
2	Association between false negative hepatobiliary scans and initial gallbladder visualization after 30 min. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>1990</b> , 16, 747-53		5
1	Adaptive post-transcriptional reprogramming of metabolism limits response to targeted therapy in BRAFV600 melanoma		1